NovoCure NVCR
- Market cap
- $1.5B
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 2.1×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $725.4M
- +13% on a year ago
- Net margin
- −16.8%
- Free cash flow yield
- −1.6%
NovoCure trades at 2.1× sales. Its trailing earnings are negative, so it has no PE. Revenue was $725.4M over the last twelve months, up 13% on a year earlier with a −17% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $133.8M+4% | $138.5M+13% | $150.4M+19% | $155.1M+22% | $161.3M+21% | $155M+12% | $158.8M+6% | $167.2M+8% | $174.3M+8% | $174.1M+12% | $183.6M+16% | $193.4M+16% | |
| Cost of revenue | $32.6M+13% | $33.7M+14% | $34.7M+2% | $35.4M+10% | $33.5M+3% | $38.5M+14% | $41.5M+20% | $44.7M+27% | $42.2M+26% | $38.9M+1% | $41.1M−1% | $44.5M−0% |
| Gross profit | $101.2M+2% | $104.8M+13% | $115.7M+26% | $119.7M+26% | $127.8M+26% | $116.5M+11% | $117.3M+1% | $122.5M+2% | $132.2M+3% | $135.1M+16% | $142.5M+21% | $148.9M+22% |
| R&D | $54.3M−1% | $51.6M−14% | $55M−1% | $51.9M−3% | $51.2M−6% | $53.8M+4% | $55.8M+2% | $54M+4% | $60.9M+19% | $58.3M+9% | $51.4M−8% | $58.1M+8% |
| SG&A | $98.6M+13% | $94.7M+2% | $94.3M−5% | $99.9M+0% | $139.9M+42% | $100.6M+6% | $101M+7% | $104.5M+5% | $111.7M−20% | $144.2M+43% | $101.6M+1% | $96.9M−7% |
| −$51.7M+20% | −$41.5M−31% | −$33.6M−46% | −$32.1M−45% | −$63.3M+22% | −$37.9M−9% | −$39.5M+18% | −$36M+12% | −$40.4M−36% | −$67.4M+78% | −$10.6M−73% | −$6.2M−83% | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pre-tax income | −$38.5M+18% | −$31.6M−38% | −$22.7M−58% | −$21.6M−55% | −$55.2M+43% | −$30.3M−4% | −$35M+54% | −$30M+39% | −$41M−26% | −$69.3M+129% | −$12.5M−64% | −$7.9M−74% |
| $8.5M+80% | $7.1M+259% | $10.6M+203% | $9M+611% | $10.7M+25% | $4M−44% | $5.2M−52% | $7.2M−19% | −$16.5M | $1.9M−53% | $3.2M−38% | $2.6M−65% | |
| Net income | −$47.1M+26% | −$38.8M−27% | −$33.4M−42% | −$30.6M−38% | −$65.9M+40% | −$34.3M−12% | −$40.1M+20% | −$37.3M+22% | −$24.5M−63% | −$71.1M+107% | −$15.7M−61% | −$10.4M−72% |
| −$0.44+22% | −$0.36−28% | −$0.31−43% | −$0.28−39% | −$0.61+39% | −$0.31−14% | −$0.36+16% | −$0.33+18% | −$0.22−64% | −$0.62+100% | −$0.13−64% | −$0.09−73% | |
| 106.9M+2% | 107.3M+2% | 107.7M+1% | 108.2M+1% | 108.3M+1% | 110.3M+3% | 111.6M+4% | 111.9M+3% | 112.1M+4% | 114.1M+4% | 116M+4% | 116.8M+4% |
EPS, diluted: 5 periods, Q4 FY14 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 4 periods, Q4 FY14 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest NovoCure's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| NVCRNovoCure | $1.5B | n/m | n/a | 2.1× | +13% | −16.8% | |
| EYENational Vision | $1.4B | 28.1× | 52.7× | 0.7× | +8% | 2.5% | |
| CDRECadre | $1.3B | 38.9× | 35.9× | 2.0× | +20% | 5.3% | |
| LMATLemaitre Vascular | $1.9B | 28.5× | 42.0× | 7.1× | +12% | 25.0% | |
| STAAStaar Surgical | $1.3B | 356× | 144× | 3.7× | +51% | 1.1% | |
| INSPInspire Medical Systems | $1.9B | 14.5× | 56.6× | 2.2× | −0% | 15.0% | |
| BVSBioventus | $1.1B | 17.1× | 27.1× | 1.9× | +4% | 9.4% | |
| UFPTUFP Technologies | $2.2B | 30.6× | 25.6× | 3.5× | +7% | 11.4% | |
| IARTIntegra Lifesciences | $1.1B | 80.1× | 46.3× | 0.6× | +1% | 0.8% | |
| IRMDIradimed | $1B | 42.5× | 41.5× | 11.4× | +11% | 26.8% | |
| WRBYWarby Parker | $2.9B | 341× | 359× | 3.2× | +11% | 0.8% | |
| Peer median | $1.4B | 34.8× | 44.1× | 2.7× | +9% | 7.3% |
Investors who own it
Investors we follow who held NovoCure at the end of Jun 30, 2026, from their 13F filings.
- Baillie GiffordBaillie Gifford0.0% of portfoliotrimmed
More on NovoCure
Each number over time
- PE ratio
- Price to sales ratio
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .